Dopamine Reuptake Transporter (DAT) “Inverse Agonism” E Anovel 66 2 67 3 Hypothesis to Explain the Enigmatic Pharmacology of Cocaine 68 4 * 69 5 Q5 David J

Total Page:16

File Type:pdf, Size:1020Kb

Dopamine Reuptake Transporter (DAT) “Inverse Agonism” E Anovel 66 2 67 3 Hypothesis to Explain the Enigmatic Pharmacology of Cocaine 68 4 * 69 5 Q5 David J NP5526_proof ■ 24 June 2014 ■ 1/22 Neuropharmacology xxx (2014) 1e22 55 Contents lists available at ScienceDirect 56 57 Neuropharmacology 58 59 60 journal homepage: www.elsevier.com/locate/neuropharm 61 62 63 64 65 1 Dopamine reuptake transporter (DAT) “inverse agonism” e Anovel 66 2 67 3 hypothesis to explain the enigmatic pharmacology of cocaine 68 4 * 69 5 Q5 David J. Heal , Jane Gosden, Sharon L. Smith 70 6 71 RenaSci Limited, BioCity, Pennyfoot Street, Nottingham NG1 1GF, UK 7 72 8 73 9 article info abstract 74 10 75 11 76 Article history: The long held view is cocaine's pharmacological effects are mediated by monoamine reuptake inhibition. 12 Available online xxx However, drugs with rapid brain penetration like sibutramine, bupropion, mazindol and tesofensine, 77 13 which are equal to or more potent than cocaine as dopamine reuptake inhibitors, produce no discernable 78 14 Keywords: subjective effects such as drug “highs” or euphoria in drug-experienced human volunteers. Moreover 79 15 Cocaine they are dysphoric and aversive when given at high doses. In vivo experiments in animals demonstrate 80 16 Dopamine reuptake inhibitor that cocaine's monoaminergic pharmacology is profoundly different from that of other prescribed 81 Dopamine releasing agent 17 monoamine reuptake inhibitors, with the exception of methylphenidate. These findings led us to 82 Dopamine transporter fi 18 Inverse agonist conclude that the highly unusual, stimulant pro le of cocaine and related compounds, eg methylphe- 83 19 DAT inverse agonist nidate, is not mediated by monoamine reuptake inhibition alone. 84 We describe the experimental findings which suggest cocaine serves as a negative allosteric 20 Novel mechanism 85 21 modulator to alter the function of the dopamine reuptake transporter (DAT) and reverse its direction of fi 86 22 transport. This results in a ring-dependent, retro-transport of dopamine into the synaptic cleft. The proposed mechanism of cocaine is, therefore, different from other small molecule negative allostereric 87 23 modulators of the monoamine reuptake transporters, eg SoRI-6238, which merely reduce the rate of 88 24 inward transport. Because the physiological role of DAT is to remove dopamine from the synapse and the 89 25 action of cocaine is the opposite of this, we have postulated that cocaine's effect is analogous to an in- 90 26 verse agonist. If this hypothesis is validated then cocaine is the prototypical compound that exemplifies a 91 27 new class of monoaminergic drugs; DAT “inverse agonists”. 92 28 This article is part of a Special Issue entitled ‘CNS Stimulants’. 93 © 29 2014 Elsevier Ltd. All rights reserved. 94 30 95 31 96 32 97 33 98 1. Introduction 10-fold more potent as a dopamine reuptake inhibitor (Cheetham 34 99 et al., 1993, 1996; Heal et al., 1998b) than cocaine (Kula and 35 100 It was our experience in developing the centrally-acting, anti- Baldessarini, 1991; Hyttel, 1982; Richelson and Pfenning, 1984; 36 ® ® 101 obesity drug, sibutramine (Meridia , Reductil ), which raised Rothman et al., 2001) and very rapidly penetrated the brain (Heal 37 102 serious doubts about the hypothesis that cocaine's pharmacological et al., 1992), fail to mimic the psychostimulant actions of cocaine? 38 103 effects were solely mediated by monoamine reuptake inhibition. As a consequence, an enormous amount of preclinical and clinical 39 104 Sibutramine is an interesting molecule because it contains the b- testing was performed to attempt to demonstrate that sibutramine 40 105 phenylethylamine substructure that is present in many monoamine was pharmacologically different from both D-amphetamine and 41 106 releasing agents, eg D-amphetamine, methamphetamine and cocaine. The most compelling evidence came from studies in drug- 42 107 MDMA. In addition, sibutramine's active metabolites inhibited the experienced human volunteers where sibutramine did not produce 43 108 reuptake of noradrenaline (norepinephrine), 5-hydroxytryptamine positive effects, eg “Drug liking”, “High”, “Euphoria” or “Want to 44 109 (5-HT, serotonin) and dopamine (Cheetham et al., 1993, 1996; Heal take drug again” (Cole et al., 1998; Schuh et al., 2000). On the 45 110 et al., 1998b), which raised the question of its pharmacological contrary, sibutramine produced no discernable subjective effects at 46 111 similarity to cocaine. How could sibutramine, which was in effect low dose and was dysphoric and aversive at high dose (Cole et al., 47 112 1998; Schuh et al., 2000). 48 113 Subsequently, it has emerged that the clinical findings with 49 114 sibutramine were not an anomaly, and have now been replicated 50 * Corresponding author. Tel.: þ44 (0) 115 9124260; fax: þ44 (0) 115 9124263. 115 many times with other monoamine reuptake inhibitors, eg bupro- 51 E-mail addresses: [email protected] (D.J. Heal), [email protected] 116 (S.L. Smith). pion, mazindol and tesofensine. Furthermore, in vivo experiments in 52 117 53 http://dx.doi.org/10.1016/j.neuropharm.2014.06.012 118 54 0028-3908/© 2014 Elsevier Ltd. All rights reserved. 119 Please cite this article in press as: Heal, D.J., et al., Dopamine reuptake transporter (DAT) “inverse agonism” e A novel hypothesis to explain the enigmatic pharmacology of cocaine, Neuropharmacology (2014), http://dx.doi.org/10.1016/j.neuropharm.2014.06.012 NP5526_proof ■ 24 June 2014 ■ 2/22 2 D.J. Heal et al. / Neuropharmacology xxx (2014) 1e22 1 animals have revealed that cocaine's monoaminergic pharmacology following sections, we will critically assess validity of the evidence 66 2 is profoundly different from that of clinically used monoamine re- in support of the DAT inhibitor hypothesis for cocaine. 67 3 uptake inhibitor drugs with the exception of methylphenidate. 68 4 Together, these observations have led us to the conclusion that the 2.1. All dopamine reuptake inhibitors are stimulant euphoriants 69 5 highly unusual, stimulant profile of cocaine and related compounds 70 6 is not mediated by reuptake inhibition alone. In this review, we put Although observations made using animal models have excel- 71 7 forward the hypothesis that cocaine allosterically modulates the lent predictive validity with regard to the recreational abuse lia- 72 8 function of the dopamine reuptake transporter (DAT) to reverse its bility of compounds from many pharmacological classes, the 73 9 direction of transport, resulting in a firing-dependent retrotransport monoamine reuptake inhibitors are problematic in this respect (see 74 10 of dopamine into the synaptic cleft. The proposed action of cocaine review by Freeman et al., this issue). In recent years, there has been 75 11 is, therefore totally different from that of related, small molecule, increasing pressure from regulators to explore recreational abuse 76 12 negative allostereric modulators of monoamine reuptake trans- liability of novel CNS-active drug-candidates in drug-experienced 77 13 porters, eg SoRI-6238, which only reduce the rate of inward trans- human volunteers. From these observations, there is a growing 78 14 port (Nandi et al., 2004). Since the physiological role of DAT is to body of definitive information from reuptake inhibitors with a widely 79 15 remove dopamine from the synapse, we have postulated that co- differing balance of reuptake inhibitory actions across the spectrum 80 16 caine's effect is analogous to that of an inverse agonist. If this hy- of monoamines that sheds light on the question of whether all DAT 81 17 pothesis proves to be valid then cocaine is the prototypical inhibitors have the capacity to be stimulant euphoriants. 82 18 compound that exemplifies a new class of monoaminergic drugs; As shown in Table 1, cocaine, which is a non-selective mono- 83 19 the DAT “inverse agonists”. amine reuptake inhibitor (Hyttel, 1982; Richelson and Pfenning, 84 20 1984; Andersen, 1989), unequivocally and reproducibly produces 85 21 2. Exploring the myths pleasurable energisation (stimulation), and feelings of wellbeing 86 22 and elation (euphoria) that are reflected in subjective reports of 87 23 When a drug has been the subject of scientific research for de- “drug liking”. 88 24 cades, there is often a prevailing view that its mechanism of action Methylphenidate, which is a catecholamine reuptake inhibitor 89 25 has been fully elucidated and there is nothing new to be learnt. In (Hyttel, 1982; Richelson and Pfenning, 1984; Andersen, 1989), also 90 26 this situation there is a tendency for a hypothesis that is based on evokes subjective effects in drug-experienced human volunteers 91 27 sound scientific observations to become dogma. Dogma which is and normal healthy subjects that are similar to those produced by 92 28 often accompanied by an unwillingness to concede that when the the highly abused psychostimulants, i.e. cocaine or amphetamine 93 29 facts no longer fit the hypothesis, it is the hypothesis and not the (Martin et al., 1971; Smith and Davis, 1977; Heishman and 94 30 facts that needs to be re-evaluated. Cocaine may turn out to be Henningfield, 1991; Rush et al., 2001; Rush and Baker, 2001; see 95 31 another classic example. also reviews by Kollins et al., 2001; Huss and Lehmkuhl, 2002; Klein 96 32 Although it was already well established that cocaine potenti- Schwartz, 2002; Kollins, 2003, Table 1). Specifically, under “blin- 97 33 ated the effects of noradrenaline in peripheral tissues and this ef- ded” experimental conditions, methylphenidate has been reported 98 34 fect was pronounced in areas where there was dense sympathetic to generalise to the cocaine cue in normal human volunteers and 99 35 innervation (Trendelenburg, 1965, 1966, 1969), it was the seminal stimulant abusers who have been trained to discriminate between 100 36 work of Iversen and colleagues that led to the discovery that cocaine and placebo (Rush and Baker, 2001; Rush et al., 2002b). 101 37 cocaine was a competitive inhibitor of high-affinity, noradrenaline These subjects also reported levels of “drug liking” and “stimula- 102 38 uptake transport (Uptake-1) in the heart.
Recommended publications
  • Antinociceptive Effects of Monoamine Reuptake Inhibitors in Assays of Pain-Stimulated and Pain-Depressed Behaviors
    Virginia Commonwealth University VCU Scholars Compass Theses and Dissertations Graduate School 2012 Antinociceptive Effects of Monoamine Reuptake Inhibitors in Assays of Pain-Stimulated and Pain-Depressed Behaviors Marisa Rosenberg Virginia Commonwealth University Follow this and additional works at: https://scholarscompass.vcu.edu/etd Part of the Medical Pharmacology Commons © The Author Downloaded from https://scholarscompass.vcu.edu/etd/2715 This Thesis is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars Compass. For more information, please contact [email protected]. ANTINOCICEPTIVE EFFECTS OF MONOAMINE REUPTAKE INHIBITORS IN ASSAYS OF PAIN-STIMULATED AND PAIN-DEPRESSED BEHAVIOR A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science at Virginia Commonwealth University By Marisa B. Rosenberg Bachelor of Science, Temple University, 2008 Advisor: Sidney Stevens Negus, Ph.D. Professor, Department of Pharmacology/Toxicology Virginia Commonwealth University Richmond, VA May, 2012 Acknowledgement First and foremost, I’d like to thank my advisor Dr. Steven Negus, whose unwavering support, guidance and patience throughout my graduate career has helped me become the scientist I am today. His dedication to education, learning and the scientific process has instilled in me a quest for knowledge that I will continue to pursue in life. His thoroughness, attention to detail and understanding of pharmacology has been exemplary to a young person like me just starting out in the field of science. I’d also like to thank all of my committee members (Drs.
    [Show full text]
  • Expansion of a Cheminformatic Database of Spectral Data for Forensic Chemists and Toxicologists
    The author(s) shown below used Federal funds provided by the U.S. Department of Justice and prepared the following final report: Document Title: Expansion of a Cheminformatic Database of Spectral Data for Forensic Chemists and Toxicologists Author(s): Peter Stout, Katherine Moore, Megan Grabenauer, Jeri Ropero-Miller Document No.: 241444 Date Received: March 2013 Award Number: 2010-DN-BX-K177 This report has not been published by the U.S. Department of Justice. To provide better customer service, NCJRS has made this Federally- funded grant report available electronically. Opinions or points of view expressed are those of the author(s) and do not necessarily reflect the official position or policies of the U.S. Department of Justice. Award Number: 2010-DN-BX-K177 July 16, 2012 Expansion of a Cheminformatic Database of Spectral Data for Forensic Chemists and Toxicologists Final Report Authors: Peter Stout Katherine Moore Megan Grabenauer Jeri Ropero-Miller This document is a research report submitted to the U.S. Department of Justice. This report has not been published by the Department. Opinions or points of view expressed are those of the author(s) and do not necessarily reflect the official position or policies of the U.S. Department of Justice. Expansion of a Cheminformatic Database of Spectral Data for Forensic Chemists and Toxicologists Table of Contents Abstract ........................................................................................................................................... 1 Executive Summary .......................................................................................................................
    [Show full text]
  • Director's Report 2/01
    Director's Report 2/01 Director's Report to the National Advisory Council on Drug Abuse February, 2001 Index Research Findings Basic Research Behavioral Research Treatment Research and Development Research on AIDS and Other Medical Consequences of Drug Abuse Epidemiology, Etiology and Prevention Research Services Research Intramural Research Program Activities Extramural Policy and Review Activities Congressional Affairs International Activities Meetings and Conferences Media and Education Activities Planned Meetings Publications Staff Highlights Grantee Honors [Office of Director] [First Report Section] Archive Home | Accessibility | Privacy | FOIA (NIH) | Current NIDA Home Page The National Institute on Drug Abuse (NIDA) is part of the National Institutes of Health (NIH) , a component of the U.S. Department of Health and Human Services. Questions? _ See our Contact Information. https://archives.drugabuse.gov/DirReports/DirRep201/DirectorRepIndex.html[11/17/16, 9:48:57 PM] Director's Report 2/01 - Basic Research Director's Report to the National Advisory Council on Drug Abuse February, 2001 Research Findings Basic Research Role for GDNF in Biochemical and Behavioral Adaptations to Drugs of Abuse Drs. David Russell and Eric Nestler and their research team at the Yale University examined a role for Glial-Derived Neurotrophic Factor (GDNF) in adaptations to drugs of abuse. Infusion of GDNF into the ventral tegmental area (VTA), a dopaminergic brain region important for addiction, blocks certain biochemical adaptations to chronic cocaine or morphine as well as the rewarding effects of cocaine. Conversely, responses to cocaine are enhanced in rats by intra-VTA infusion of an anti-GDNF antibody and in mice heterozygous for a null mutation in the GDNF gene.
    [Show full text]
  • Drugs and New Potentially Dangerous Chemical Substances, with a Brief Review of the Problem
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL & SCIENCE EDUCATION 2016, VOL. 11, NO. 14, 6697-6703 OPEN ACCESS Approach to Classifying “Design” Drugs and New Potentially Dangerous Chemical Substances, With a Brief Review of the Problem Azat R. Asadullina, Elena Kh. Galeevab, Elvina A. Achmetovaa and Ivan V. Nikolaevb aBashkir State Medical University of the Ministry of Health of the Russian Federation, Ufa, RUSSIA; bRepublican Narcological Dispensary No.1 of the Ministry of Health of the Republic of Bashkortostan, Ufa, RUSSIA ABSTRACT The urgency of this study has become vivid in the light of the growing problem of prevalence and bBPHFuse Republican of new synthetic Narcological drug types. DispensaryLately there has No.1 been of a thetendency Ministry of expanding of Health the rangeof the of psychologically active substances (PAS) used by addicts with the purpose of their illegal taking. RepublicThe aim of Bashkortostan,of this research is anPushkin attempt str.,of systematizing 119/1, Ufa, and RB. classifying “design” drugs according to their chemical structure, neurochemical mechanisms of action and clinical manifestations. As a result, we have found that they can be divided into ten big groups. This classification will allow to better arrange new clinical phenomenology in modern addictology. This paper would be useful for psychiatrists, experts in narcology, as well as for personnel of institutions and agencies engaged in anti-drug activity. KEYWORDS ARTICLE HISTORY Opiates, cannabinoids, cathinones, tryptamine, Received 20 April 2016 cocaine, pregabalin, new “design” drugs, Revised 28 May 2016 classification Accepted 29 Мау 2016 Introduction Urgency of the problem Recently, the sphere of illegal turnover of narcotic substances has shown an apparent trend of producing the so-called “design drugs” (DN): new potentially dangerous psychologically active substances (NPDPAS) obtained by means of chemical synthesis, possessing a high narcotic effect and manufactured with the CORRESPONDENCE Azat R.
    [Show full text]
  • World of Cognitive Enhancers
    ORIGINAL RESEARCH published: 11 September 2020 doi: 10.3389/fpsyt.2020.546796 The Psychonauts’ World of Cognitive Enhancers Flavia Napoletano 1,2, Fabrizio Schifano 2*, John Martin Corkery 2, Amira Guirguis 2,3, Davide Arillotta 2,4, Caroline Zangani 2,5 and Alessandro Vento 6,7,8 1 Department of Mental Health, Homerton University Hospital, East London Foundation Trust, London, United Kingdom, 2 Psychopharmacology, Drug Misuse, and Novel Psychoactive Substances Research Unit, School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom, 3 Swansea University Medical School, Institute of Life Sciences 2, Swansea University, Swansea, United Kingdom, 4 Psychiatry Unit, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy, 5 Department of Health Sciences, University of Milan, Milan, Italy, 6 Department of Mental Health, Addictions’ Observatory (ODDPSS), Rome, Italy, 7 Department of Mental Health, Guglielmo Marconi” University, Rome, Italy, 8 Department of Mental Health, ASL Roma 2, Rome, Italy Background: There is growing availability of novel psychoactive substances (NPS), including cognitive enhancers (CEs) which can be used in the treatment of certain mental health disorders. While treating cognitive deficit symptoms in neuropsychiatric or neurodegenerative disorders using CEs might have significant benefits for patients, the increasing recreational use of these substances by healthy individuals raises many clinical, medico-legal, and ethical issues. Moreover, it has become very challenging for clinicians to Edited by: keep up-to-date with CEs currently available as comprehensive official lists do not exist. Simona Pichini, Methods: Using a web crawler (NPSfinder®), the present study aimed at assessing National Institute of Health (ISS), Italy Reviewed by: psychonaut fora/platforms to better understand the online situation regarding CEs.
    [Show full text]
  • DOPAMINE TRANSPORTER in ALCOHOLISM a SPET Study
    DOPAMINE TRANSPORTER IN PEKKA ALCOHOLISM LAINE A SPET study Departments of Psychiatry and Clinical Chemistry, University of Oulu Department of Forensic Psychiatry, University of Kuopio Department of Clinical Physiology and Nuclear Medicine, University of Helsinki OULU 2001 PEKKA LAINE DOPAMINE TRANSPORTER IN ALCOHOLISM A SPET study Academic Dissertation to be presented with the assent of the Faculty of Medicine, University of Oulu, for public discussion in the Väinö Pääkkönen Hall of the Department of Psychiatry (Peltolantie 5), on November 30th, 2001, at 12 noon. OULUN YLIOPISTO, OULU 2001 Copyright © 2001 University of Oulu, 2001 Manuscript received 12 October 2001 Manuscript accepted 16 October 2001 Communicated by Professor Esa Korpi Professor Matti Virkkunen ISBN 951-42-6527-0 (URL: http://herkules.oulu.fi/isbn9514265270/) ALSO AVAILABLE IN PRINTED FORMAT ISBN 951-42-6526-2 ISSN 0355-3221 (URL: http://herkules.oulu.fi/issn03553221/) OULU UNIVERSITY PRESS OULU 2001 Laine, Pekka, Dopamine transporter in alcoholism A SPET study Department of Clinical Chemistry, Division of Nuclear Medicine, University of Oulu, P.O.Box 5000, FIN-90014 University of Oulu, Finland, Department of Forensic Psychiatry, University of Kuopio, , FIN-70211 University of Kuopio, Finland, Department of Clinical Physiology and Nuclear Medicine, Division of Nuclear Medicine, University of Helsinki, P.O. Box 340, FIN-00029 Helsinki, Finland, Department of Psychiatry, University of Oulu, P.O.Box 5000, FIN-90014 University of Oulu, Finland 2001 Oulu, Finland (Manuscript received 12 October 2001) Abstract A large body of animal studies indicates that reinforcement from alcohol is associated with dopaminergic neurotransmission in the mesocorticolimbic pathway. However, as most psychiatric phenomena cannot be studied with animals, human studies are needed.
    [Show full text]
  • The Pharmacology of an Agonist Medication to Treat Stimulant Use Disorder
    Virginia Commonwealth University VCU Scholars Compass Theses and Dissertations Graduate School 2017 The Pharmacology of an Agonist Medication to Treat Stimulant Use Disorder Amy Johnson johnsonar24 Follow this and additional works at: https://scholarscompass.vcu.edu/etd © Amy Johnson Downloaded from https://scholarscompass.vcu.edu/etd/5177 This Dissertation is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars Compass. For more information, please contact [email protected]. © Amy R. Johnson 2017 All Rights Reserved The Pharmacology of an Agonist Medication to Treat Stimulant Use Disorder A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy at Virginia Commonwealth University by Amy R. Johnson Bachelor of Science, University of Wisconsin - Eau Claire, 2013 Advisor: S. Stevens Negus, PhD Professor of Pharmacology and Toxicology Virginia Commonwealth University Virginia Commonwealth University Richmond, VA November, 2017 Acknowledgements Thank you to all the people who made this dissertation possible. I would like to thank my family for their support and belief in me. Many thanks to my dissertation advisor, Steve Negus, for his guidance, knowledge, patience, and encouragement. Thank you to Katherine Nicholson and Matthew Banks, each of whom guided me through a different procedure through the course of my research and served on my committee. Thanks to my remaining committee members, Lori Keyser-Marcus and Jose Eltit, for their time and commitment to my project. Thank you to my entire committee for helping to develop and mold me as a scientist.
    [Show full text]
  • Cocaine Interaction with Dopamine Transporter in the Prefrontal Cortex and Beyond
    Central Journal of Substance Abuse & Alcoholism Bringing Excellence in Open Access Review Article *Corresponding author Ezio Carboni, Department of Biomedical Sciences, University of Cagliari, Via Ospedale 72, 09126, Cagliari, Cocaine Interaction with Italy, Email: Submitted: 18 March 2017 Accepted: 28 February 2018 Dopamine Transporter in the Published: 28 February 2018 ISSN: 2373-9363 Prefrontal Cortex and Beyond Copyright © 2018 Carboni et al. Ezio Carboni1,2*, Elena Carboni3, and Dragana Jadzic1 OPEN ACCESS 1Dept. of Biomedical Sciences, University of Cagliari, Italy 2Neuroscience Institute, National Research Council of Italy - CNR, Italy Keywords 3Unit of Pediatrics, University Magna Graecia of Catanzaro, Italy • Cocaine • Monoamine transporters Abstract • Prefrontal cortex • Nucleus accumbens Although the relevant research investment in understanding the mechanism of action of • Bed nucleus of stria terminalis cocaine and its role in altering brain circuits and behaviour, an efficacious therapy for cocaine addiction has not been found yet. Thus, cocaine use, dependence, abuse and addiction are still a relevant health, social, and economical problem. Cocaine interacts with three different monoamine transporters and increases the extracellular level of dopamine, norepinephrine and serotonin in many brain areas as well in periphery. The aim of this review is to evaluate the interaction of cocaine with the dopamine transporter (DAT) but also with the norepinephrine transporter (NET) and the serotonin transporter (SERT) in several brain
    [Show full text]
  • Amphetamine Primes Motivation to Gamble and Gambling- Related Semantic Networks in Problem Gamblers
    Neuropsychopharmacology (2004) 29, 195–207 & 2004 Nature Publishing Group All rights reserved 0893-133X/04 $25.00 www.neuropsychopharmacology.org Amphetamine Primes Motivation to Gamble and Gambling- Related Semantic Networks in Problem Gamblers Martin Zack*,1,2 and Constantine X Poulos1,3 1 2 Centre for Addiction and Mental Health, Toronto, Ontario, Canada M5S 2S1; Departments of Pharmacology and Public Health Sciences, University of Toronto, Toronto, Ontario, Canada M5S 1A8; 3Department of Psychology, University of Toronto, Toronto, Ontario, Canada M5S 3G3 Previous research suggests that gambling can induce effects that closely resemble a psychostimulant drug effect. Modest doses of addictive drugs can prime motivation for drugs with similar properties. Together, these findings imply that a dose of a psychostimulant drug could prime motivation to gamble in problem gamblers. This study assessed priming effects of oral D-amphetamine (AMPH) (30 mg) in a within-subject, counter-balanced, placebo-controlled design in problem gamblers (n ¼ 10), comorbid gamblerdrinkers (n ¼ 6), problem drinkers (n ¼ 8), and healthy controls (n ¼ 12). Modified visual analog scales assessed addictive motivation and subjective effects. A modified rapid reading task assessed pharmacological activation of words from motivationally relevant and irrelevant semantic domains (Gambling, Alcohol, Positive Affect, Negative Affect, Neutral). AMPH increased self-reported motivation for gambling in problem gamblers. Severity of problem gambling predicted positive subjective effects of AMPH and motivation to gamble under the drug. There was little evidence that AMPH directly primed motivation for alcohol in problem drinkers. On the reading task, AMPH produced undifferentiated improvement in reading speed to all word classes in Nongamblers. By contrast, in the two problem gambler groups, AMPH improved reading speed to Gambling words while profoundly slowing reading speed to motivationally irrelevant Neutral words.
    [Show full text]
  • Mechanisms of Cocaine Abuse and Toxicity
    Mechanisms of Cocaine Abuse and Toxicity U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol, Drug Abuse, and Mental Health Administration I Mechanisms of Cocaine Abuse and Toxicity Editors: Doris Clouet, Ph.D. Khursheed Asghar, Ph.D. Roger Brown, Ph.D. Division of Preclinical Research National Institute on Drug Abuse NIDA Research Monograph 88 1988 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, DC 20402 NIDA Research Monographs are prepared by the research divisions of the National Institute on Drug Abuse and published by its Office of Science. The primary objective of the series is to provide critical reviews of research problem areas and techniques, the content of state-of-the-art conferences, and integrative research reviews. Its dual publication emphasis is rapid and targeted dissemination to the scientific and professional community. Editorial Advisors MARTIN W. ADLER, Ph.D. MARY L. JACOBSON Temple University School of Medicine National Federation of Parents for Philadelphia,Pennsylvania Drug-Free Youth Omaha, Nebraska SYDNEY ARCHER, Ph.D. Rensselaer Polytechnic lnstitute Troy, New York REESE T. JONES, M.D. Langley Porter Neuropsychiatric lnstitute RICHARD E. BELLEVILLE, Ph.D. San Francisco, California NB Associates, Health Sciences RockviIle, Maryland DENISE KANDEL, Ph.D. KARST J. BESTEMAN College of Physicians and Surgeons of Alcohol and Drug Problems Association Columbia University of North America New York, New York Washington, D.C. GILBERT J.
    [Show full text]
  • Importance of Assessment of Drug Self Administration Dose-Effect Curves Takato Hiranita* Division of Neurotoxicology, National Center for Toxicological Research, U.S
    lism and D ho ru o g lc D A e p f e o Journal of n l Hiranita, J Alcohol Drug Depend 2015, 3:3 d a e n r n c u e o DOI: 10.4172/2329-6488.1000e121 J ISSN: 2329-6488 Alcoholism & Drug Dependence EditorialResearch Article OpenOpen Access Access Medications Discovery: Importance of Assessment of Drug Self Administration Dose-Effect Curves Takato Hiranita* Division of Neurotoxicology, National Center for Toxicological Research, U.S. Food and Drug Administration, 3900 NCTR Road, Jefferson, AR 72079-9501, USA There are several procedures for assessment of abuse liability/ potential in laboratory animals. Among them is an intravenous (IV) drug self-administration procedure that is the gold standard. For example, the IV drug self-administration procedure has high face, predictive and construct validities [1,2]. In addition, the procedure also has lower rates of false positives and negatives, relative to other procedures [2,3]. For these reasons, the procedure has been employed for assessment of various compounds for abuse potential in humans. Figure 1: Three representative patterns of shifts in dose-effect curves of For example, drugs abused by humans (cocaine, methamphetamine, drug self administration. Lines indicate basal dose-effect curves. Dashed heroin, and ketamine) maintain self-administration responding above lines indicate dose-effect curves when pretreated. Panel A. a leftward shift. Panel B. a downward shift. Panel C. a rightward shift. vehicle levels in rats [4,5]. When such a response is maintained above vehicle levels in laboratory animals, a test compound would likely be FDA. The information in the present article is not a formal dissemination of reinforcing and have abuse potential in humans.
    [Show full text]
  • List of SSRI Effects Spirits for MD Widespread Use of Antidepressants
    List of SSRI Effects Spirits for MD widespread use of antidepressants in new SSRI-era, 2C family, 5-HT2Ay overactivity, 5-HT pro-drugs, abdominal distension, abnormal brain states, Abnormal Dreams, abnormal personalities, Abnormal Thinking, abnormally extreme emotions, abrupt cessation, abrupt interruption therapy, Acting aggressive, acting on dangerous impulses, active metabolite, acute pharma- cological action of meds, adaptation phase, & theory, addictions, Adhyperforin, adverse drug reaction, adverse effects, Advil, affect newborns, affect reuptake inhibition of serotonin & norepinephrine, aggression, aggressiveness, agitation, agomelatine, agoraphobia, akathisia, Alaproclate, alcohol use, alcohol Abuse, alcohol mixed with meds, alcoholism, Aleve, Allosteric serotonin reuptake inhibitor, alprazolam, altering hormones, alteration of neuronal activity in central nervous system, altered brain, altered mind, altered thinking, ambien, Amitifadine, amitriptyline, Amnesia, Amoxapine, Anafranil, analgesic, anorexia nervosa, anorgasmia, anti- depressant withdrawal aids, Anti-inflammatory, antiarrhythmic agents, antidepressant activity, Antidepressant Nightmares, antidepressant withdrawal symptoms, antidepressant-associated mania, antidepressant- associated psychosis, antidepressants, antipsychotic diphenylbutylpiperidine derivative, anxiety, anxiety related disorders, appetite changes, Aropax, arson, Asentra, Aspirin, ASA, Attempted Murder, Attempted suicide, auditory hallucinations, autism, autoimmune hypersensitivity, autonomic dysfunctions,
    [Show full text]